Dentsu invests in molecular-level connected health device Cue
Denstu Ventures, the investment arm of Dentsu, has invested in Cue, a device that allows people to track health changes at a molecular level at home via a smartphone app.
The device allows people to track changes such as levels of vitamin D, testosterone, inflammation, influenza and fertility by taking a small sample of blood, saliva or mucus that has been collected and added to a colour-coded cartridge which is then inserted into the Cue hardware device.
The level of investment hasn’t been disclosed but Dentsu said that much like its other investments, in addition to funding, it will also provide support from resources that are unique to the group.
In this instance, Cue plans to launch in markets including Europe and Hong Kong in the next six months, with the US and Japan following later in the year. Advertising and media resource will be key for the start-up during such a heavy growth phase.
Dentsu Ventures launched in April last year with the objectives of “investing in ambitious start-up companies that will create an as yet unseen future and furthering open innovation across the Dentsu Group through collaboration with investees,” according to the business. Cue marks the fifth investment for Dentsu Ventures.